Background: Prevention of mother-to-child transmission describes a comprehensive package of services intended to reduce mother-to-child transmission of HIV. Transmission of HIV from mother to child accounts for more than 90% of pediatric Acquired Immunodeficiency Syndrome (AIDS). Few studies examining the quality of PMTCT services provision in Ethiopia are available. Therefore, this study aimed to assess the quality of PMTCT services in public hospitals of Hadiya zone, southern Ethiopia.Methods: Institution based cross-sectional study design using both quantitative and qualitative methods was conducted in public hospitals from March 1 to April 10, 2017. A total of 423 pregnant women were consecutively interviewed at three hospitals. Service provision processes were observed for 21 counseling sessions and nine in-depth interviews were conducted with health care providers, medical director and mothers' support group. Additionally, resource inventory was done. Donabedian's Structure-Process-Outcome model was used to assess the quality of PMTCT service at respective study area. Data was analyzed using SPSS 20. Binary and multivariate logistic regressions were computed. The qualitative data were analyzed manually using thematic analysis method to support quantitative result through triangulation.Result: Most of the minimum required resources such as test kits, ARV drugs and other supplies were available in hospitals studied. However, inadequate of trained human resource was observed. About 89.8% clients were satisfied with PMTCT services provided at public hospitals. The client satisfaction with PMTCT services were associated with waiting time [AOR=4.6, 95% CI; 2.18, 9.89], counseling time [AOR=3.7, 95% CI; 1.64, 8.54] and counseling given by same counselor before and after HIV test [AOR=0.2, 95% CI; 0.09, 0.41].Discussion: Although clients' satisfaction by PMTCT service is very high. Availability of necessary resource and compliance of health care providers to national guideline need improvement. More efforts to be exerted on improving providers' compliance with national PMTCT guideline, consistent supply of necessary resources to improve quality of PMTCT services.

Introduction: Since 1974, diclofenac has been used to treat the pain and swelling associated with rheumatic illnesses as a non-steroid anti-inflammatory medication (NSAID). It is one among the world's most extensively used non-steroidal anti-inflammatory medications (NSAIDs). Non-steroidal anti-inflammatory medicines have been shown to cause embryotoxicity and teratogenicity in experimental animals in a few studies, however there is no strong evidence of this impact in people.The aim of this study was to conduct a systematic assessment of the effects of diclofenac exposure on the mother and fetus during pregnancy.Methods: This study included all experimental, quasi-experimental, and observational research that were published in the English language and published up to the date of the review. PROSPERO (The International Prospective Register of Systematic Reviews) ID = CRD42019135608 was used to register the protocol. This study employed a three-step search technique. PubMed, Medline, SCOPUS, Web of Science, Embase, cinihal, Google, several university repositories, and Google scholar were among the databases searched. The titles and abstracts were then examined by two independent reviewers to see if they met the review's inclusion criteria. At the study level, two independent reviewers critically assessed eligible studies. The review's methodological quality was assessed at the result level using standardized critical assessment instruments from the Joanna Briggs Institute (JBI) for observational studies. Specific details about the demographics, study procedures, interventions, and outcomes of significance to the review purpose are included in the data retrieved from the studies. Due to the conclusion and type of the data, statistical pooling was not viable. As a result, the results were presented in a narrative format.Results: A total of 1,490,679 participants were found in three relevant papers (two cohorts and nested case-control studies). Diclofenac exposure during pregnancy raises the chance of low birth weight in the fetus, as well as the risk of spontaneous abortion and vaginal bleeding in the mother.Conclusions: Diclofenac exposure during pregnancy has negative consequences on the fetus and the mother. As a result, taking Diclofenac during pregnancy may have negative consequences for both the mother and the fetus, and more primary Randomized Control Trials (RCTs) are needed.

INTRODUCTION Since 1974, diclofenac has been used to treat the pain and swelling associated with rheumatic illnesses as a non-steroid anti-inflammatory medication (NSAID). It is one among the world's most extensively used non-steroidal anti-inflammatory medications (NSAIDs). Non-steroidal anti-inflammatory medicines have been shown to cause embryotoxicity and teratogenicity in experimental animals in a few studies, however there is no strong evidence of this impact in people. The aim of this study was to conduct a systematic assessment of the effects of diclofenac exposure on the mother and fetus during pregnancy. METHODS This study included all experimental, quasi-experimental, and observational research that were published in the English language and published up to the date of the review. PROSPERO (The International Prospective Register of Systematic Reviews) ID=CRD42019135608 was used to register the protocol. This study employed a three-step search technique. PubMed, Medline, SCOPUS, Web of Science, Embase, cinihal, Google, several university repositories, and Google scholar were among the databases searched. The titles and abstracts were then examined by two independent reviewers to see if they met the review's inclusion criteria. At the study level, two independent reviewers critically assessed eligible studies. The review's methodological quality was assessed at the result level using standardized critical assessment instruments from the Joanna Briggs Institute (JBI) for observational studies. Specific details about the demographics, study procedures, interventions, and outcomes of significance to the review purpose are included in the data retrieved from the studies. Due to the conclusion and type of the data, statistical pooling was not viable. As a result, the results were presented in a narrative format. RESULTS A total of 1,490,679 participants were found in three relevant papers (two cohorts and nested case-control studies). Diclofenac exposure during pregnancy raises the chance of low birth weight in the fetus, as well as the risk of spontaneous abortion and vaginal bleeding in the mother. CONCLUSIONS Diclofenac exposure during pregnancy has negative consequences on the fetus and the mother. As a result, taking Diclofenac during pregnancy may have negative consequences for both the mother and the fetus, and more primary Randomized Control Trials (RCTs) are needed.